A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
Completed · Phase 1 · NCT05585632
Conditions: SARS-CoV-2, Influenza, RSV
At a glance
- Research payments reported, 2025
- $9,450
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 392
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1010 (biological), mRNA-1345 (biological), mRNA-1273.214 (biological), mRNA-1045 (biological), mRNA-1230 (biological)
- Dates
- Started 2022-10-14; completion 2024-02-28
- Results posted
- Not yet
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
From ClinicalTrials.gov, last updated 2024-03-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $9,450 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Iresearch Atlanta LLC $8,110
- Cenexel Iresearch LLC $1,340
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.